|CHDD||Home | Site Map | Search | Directory | Admin Services||
||Center on Human Development and Disability|
|About CHDD | IDDRC | UCEDD|
Dr. Juul is principal investigator on studies focusing on the neuroprotective effects of erythropoietin (Epo) in neonatal models of brain injury. She has identified Epo and its receptor in the developing human brain, demonstrated the functionality of the Epo receptor on cultured neurons, and documented Epo in the spinal fluid of human neonates. Her research shows that Epo protects the neonatal brain from injury due to hypoxia and oxidative injury.
Juul’s ultimate goal is to identify new therapeutic approaches to neonatal brain injury, determine whether they are safe and effective, and if so, bring these new treatments from the laboratory to the bedside. Using a variety of approaches and several animal models, she is working to optimize Epo treatment in the developing brain at risk for injury. This work includes studies of pharmacokinetics, drug dosing, and duration of therapy as well as identifying mechanisms of Epo neuroprotection and possible synergistic treatments. She is currently PI of a multicenter randomized controlled trial to determine whether Epo is a safe and effective neuroprotectant for extremely preterm infants. The study, Preterm Epo Neuroprotection (PENUT) is funded by NINDS, and will enroll 940 babies born between 24-0/7 and 26-6/7 weeks of gestation.
University of Washington • Center on Human Development and Disability • Box 357920 • Seattle WA 98195-7920 USA • 206-543-7701 • email@example.com
Copyright © 1996—2017 Center on Human Development and Disability. Updated: February 16, 2017